OrbiMed is distinctively structured as a "life cycle" investor in the health sciences industry. We seek the most promising investment opportunities regardless of company development stage: from private start-ups and university spinouts to the largest global pharmaceutical companies.

OrbiMed's structure combines the focus of specialized analysts dedicated to specific market sectors with the synergies of a broad investment team which spans both public and private equity.

Focus

Our team members become specialists in either public or private equity investing. Within these broad areas, analysts further specialize in disease areas, industry sub-sectors and geographic regions. This intense focus allows team members to develop a deep domain expertise, leading to more informed investment decisions.

Synergies

Significant information sharing and collaboration exists between our public and private equity analysts through shared weekly portfolio meetings, joint research projects and frequent informal interaction.

We believe these benefits provide our team with a sustainable competitive advantage and solidify our role as a capital provider of choice to the life sciences industry.